

LAND STATE DEPARTMENT OF COMMERCE Leatent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

|                    |             |                       | ATTY, DOCKET NO/TITLE |
|--------------------|-------------|-----------------------|-----------------------|
| APPLICATION NUMBER | FILING DATE | FIRST NAMED APPLICANT | ATTY, DOCKET HOSTITEE |
|                    |             |                       |                       |

08/487,283

06/07/95

**EVANS** 

ALX-152.1CIP

0252/0825

SETH A FIDEL ALEXION PHARMACEUTICALS 25 SCIENCE PARK

| SUITE 360                                       | HIMS   | DATE MAILED: 0000  | )  |
|---|--|--|--|
| NEW HAVEN C                                     | NOTICE TO FILE MISSING   | G PARTS OF APPLICATION<br>TE GRANTED   |  |
| below are missing.  THE, PAYMENT  \$            | OF A SURCHARGE for items and rees tuen<br>of a surcharge for items<br>small entities who have filed a verified | signed to this application. However<br>tified below must be timely submi<br>1 and 3-6 only of \$ (30)<br>I statement claiming such status. The   | for large entities or<br>surcharge is set forth in |
| If all required items of entity,   small entity | on this form are filed within the period (verified statement filed), is \$ 80                                  | set helow, the total amount owed by ap   | ppicant as a large                                 |
| required above to a extension fee under         | this application, WHICHEVER IS Lavoid abandonment. Extensions of tire the provisions of 37 CFR 1.136(a).       | OF THIS LETTER, OR TWO MO<br>ATER, within which to file all required<br>ne may be obtained by filing a petition  | n accompanied by the                               |
| 1. The statuto entity, mus                      | t submit \$to com  | insufficient. Applicant as a 🖂   |  |
| 2. Additional orequired more fees or cano       | claim fees of \$as<br>ultiple dependent claim fee, are r<br>el the additional claims for which                 | a □ large entity, □ small entity,<br>equired. Applicant must submit t<br>fees are due.   | including any<br>he additional claim               |
|   | g.<br>cover the newly submitted items.   |  |  |
| Application                                     | Number and Filing Date is requ   | CFR 1.63, identifying the application of the second control of the |  |
| in compliar<br>Filing Date                      | nce with 37 CFK 1.63, identifying a is required.   | application to which it applies. At the application by the above Appl  |  |
| or a persor<br>compliance<br>Filing Dat         | n qualified under 37 CFR 1.42, 1.4<br>with 37 CFR 1.63, identifying the<br>e, is required.                     | v/are: □ missing; □ by a person o<br>3, or 1.47. A properly signed oat<br>e application by the above Applica   | ation Number and                                   |
| 6.  The signat                                  | are of the following joint invento   | r(s) is missing from the oath or de  | claration:   |
| •   | An oath or decla<br>d inventor(s), identifying this app  | ration listing the names of all involution by the above Application  | entors and signed by                               |
|   | cation was filed in a language oth<br>n of the application and a fee of \$<br>sen paid.                        | er than English. Applicant must f<br>under 37 CFR 1.17(k   | ,  |
| 8. 🗆 A \$                                       | .21(m)).   | equired since your check was retu  |  |
| 9., \ Your filin                                | g receipt was mailed in error beca   | use your check was   |  |
| 10 ID The appli                                 | cation does not comply with the S<br>Rules 37 CFR 1.821-1.825.   |  | •  |
| 11. □ Other.                                    |  | -  | •  |
| Direct the response                             | onse to Box Missing 1 and  |  |  |

A copy of this not

FORM PTO-1588 (REV. 11-94)



## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACTOR SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 -1.825 for the following reason(s): This application clearly fails to comply with the requirements of 37 CFR 1.821 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c). A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing." The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d). The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e). 7. Other: -Applicant must provide:

An initial or substitute computer readable form (CRF) copy of the "Sequence

An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification ### A statement that the content of the paper and computer readable copies are the same

and, where applicable, include no new matter) as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123

For CRF submission help, call (703) 308-4212

For PatentIn software help, call (703) 557-0400